DoD Peer Reviewed Medical Technology/Therapeutic Development Award | Apply Online

DoD PRMRP Therapeutic/Medical Technology Development Award (TTDA) FAQs

1) What is the PRMRP TTDA grant opportunity?

The Peer Reviewed Medical Technology/Therapeutic Development Award (PRMRP TTDA) is a Department of Defense funding opportunity designed to move strong preclinical research results toward practical medical products that can be used in real clinical settings. It is focused on translation and development rather than basic discovery.

2) What is the main purpose of this award?

The main purpose is to advance a product candidate that already has promising preclinical support into a more developed form that is closer to patient use. The program is product-driven and expects a clear deliverable and a defined development path.

3) Is this program intended for basic research or early discovery?

No. The emphasis is not on basic discovery work. Applicants are expected to build on existing, strong preclinical results and propose a development effort that pushes a candidate product forward toward clinical application.

4) What kinds of outcomes or endpoints does the DoD expect from funded projects?

Intended endpoints include products that improve prevention, detection, diagnosis, patient care, and/or quality of life. The project should be positioned to produce a tangible product outcome rather than primarily generating exploratory knowledge.

5) What product types are considered eligible under this opportunity?

Examples of eligible product types include:

• Pharmacologic agents (such as drugs or biologics)
• Medical devices
• Clinical guidance intended to influence or establish standards of care

In all cases, the work should be organized around concrete development milestones that move the product toward clinical use.

6) Who should the product benefit?

A central requirement is that the product under development should directly address health care needs relevant to military service members, Veterans, and/or other beneficiaries. Relevance to these populations is a core expectation of the program.

7) Does the proposed work need to align with specific topic areas?

Yes. The proposed work must align with at least one of the Congressionally directed FY2014 Peer Reviewed Medical Research Program (PRMRP) Topic Areas listed in the program announcement.

8) What does “product-driven” mean in the context of this award?

“Product-driven” means the effort should have a clear deliverable and a defined plan for development, rather than being purely exploratory research. The project should be structured around practical steps and milestones that advance a candidate product toward clinical application.

9) Are development milestones expected as part of the proposed approach?

Yes. The opportunity specifically emphasizes structuring the proposed work around concrete development milestones that move the candidate product toward clinical application.

10) What is a “transition plan,” and is it required?

A credible transition plan from the Principal Investigator (PI) is a key feature and expectation of this opportunity. The transition plan must explain how the product will advance to the next stage after the award period ends.

11) What should the transition plan cover?

Based on the information provided, the transition plan is expected to address:

• How the product will advance after the award period (for example, entry into clinical trials, obtaining additional development support, or moving toward delivery and adoption)
• Likely funding sources and resources needed to support the next stage
• A realistic route to real-world implementation and impact in military and/or civilian markets

12) Which agency offered this funding opportunity?

The opportunity was offered by the Department of the Army through USAMRAA.

13) What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number listed is W81XWH-14-PRMRP-TTDA.

14) What type of funding mechanism was used (grant vs. cooperative agreement)?

The opportunity supported awards through cooperative agreements and/or grants.

15) What is the estimated total funding amount and expected number of awards?

The total estimated funding amount was $13.5 million, with an anticipated six awards.

16) Is cost sharing or matching required?

No. The opportunity listed no cost sharing or matching requirement.

17) Who was eligible to apply?

Eligibility was described as unrestricted, meaning it was generally open to a wide range of entity types, subject to any additional eligibility clarifications in the full announcement text.

18) When was the opportunity posted and when did it close?

The opportunity was posted on April 30, 2014, and the application closing date was October 17, 2014 (the same date was listed as both the original and current deadline).

19) Where can applicants get help accessing the announcement or using the submission system?

The listing provided the CDMRP Help Desk contact information for support: phone 301-682-5507 and email help@eBRAP.org.

20) What general kind of program was this categorized as?

It was categorized as a discretionary research and development program.